Spartan Bioscience

Ottawa biotech firm says it is restructuring in the wake of a “higher-than-expected level of inconclusive results” from its rapid COVID-19 testing device.
Ottawa biotech firm predicts revenues will top $200 million this year ​– and only rise from there.
Ottawa company says it plans to begin shipping the device “immediately” to federal and provincial governments as well as commercial customers.
After facing months of delays, Ottawa biotech firm is hoping its rapid testing device is poised to clear the final hurdle before it can go to market.
Chief executive Roger Eacock says rapid COVID-19 tests are poised to make local biotech company a force on the 'international stage.'
Company says it hopes to get Health Canada’s approval to market the test “in the coming weeks.” 
Ottawa firm says it has applied to Health Canada to begin clinical trials on a fix for its rapid COVID-19 testing device after the agency had concerns about the test’s effectiveness.
Ottawa biotech firm voluntarily recalled test in May after federal regulatory agency expressed concern about its effectiveness.
Canada’s flagship carrier said Tuesday it’s asked Spartan “to assess how best to employ” its technology to screen passengers and airline employees.
Ottawa company said it would recall the 5,500 test shipped nationally and work on additional clinical studies.